Financing ·
Ascentage Pharma Group International announced on July 19, 2026, the submission of an automatic shelf registration…
AAPGAscentage Pharma Group International
Ascentage Pharma Group International announced on July 19, 2026, the submission of an automatic shelf registration statement on Form F-3 with the SEC to establish an at-the-market (ATM) offering program. The program allows the company to sell American depositary shares (ADSs) for an aggregate offering price of up to $200 million through sales agents Citigroup, Deutsche Bank, and BTIG. Proceeds are intended for the commercialization of Olverembatinib and Lisaftoclax, clinical trials, and general corporate purposes. The company operates in the biotechnology industry and develops drug candidates for oncology and other diseases.